192 related articles for article (PubMed ID: 22607870)
1. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai G; Valgimigli M; Margheri M; Marzocchi A; Lettieri C; Stabile A; Petronio AS; Binetti G; Bolognese L; Bellone P; Sardella G; Contarini M; Sheiban I; Marra S; Piscione F; Romeo F; Colombo A; Sangiorgi G
Am Heart J; 2012 May; 163(5):835.e1-7. PubMed ID: 22607870
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
[TBL] [Abstract][Full Text] [Related]
3. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
[TBL] [Abstract][Full Text] [Related]
4. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
5. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
6. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
[TBL] [Abstract][Full Text] [Related]
7. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
9. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
[TBL] [Abstract][Full Text] [Related]
10. Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions: The DKCRUSH-VI Trial (Double Kissing Crush Versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions VI).
Chen SL; Ye F; Zhang JJ; Xu T; Tian NL; Liu ZZ; Lin S; Shan SJ; Ge Z; You W; Liu YQ; Qian XS; Li F; Yang S; Kwan TW; Xu B; Stone GW
JACC Cardiovasc Interv; 2015 Apr; 8(4):536-46. PubMed ID: 25819187
[TBL] [Abstract][Full Text] [Related]
11. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
12. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
14. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
Bhatt DL; Lee BI; Casterella PJ; Pulsipher M; Rogers M; Cohen M; Corrigan VE; Ryan TJ; Breall JA; Moses JW; Eaton GM; Sklar MA; Lincoff AM;
J Am Coll Cardiol; 2003 Jan; 41(1):20-5. PubMed ID: 12570939
[TBL] [Abstract][Full Text] [Related]
15. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
[TBL] [Abstract][Full Text] [Related]
16. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
18. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
[TBL] [Abstract][Full Text] [Related]
20. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]